Given the significant overlap in clinical presentations and the separate genetic associations, reclassification of AAV is being considered according to the ANCA type (PR3 versus MPO) rather than traditional clinical phenotype (GPA versus MPA). The gene discussed is PRTN3; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.